|
20 Sep 2025 |
Gland Pharma
|
Consensus Share Price Target
|
2022.80 |
1862.83 |
- |
-7.91 |
hold
|
|
|
|
|
09 Nov 2020
|
Gland Pharma
|
ICICI Securities Limited
|
2022.80
|
|
|
|
IPO Note
|
|
|
Established in Hyderabad in 1978, Gland Pharma is one of the largest and fastest growing injectable-focused B2B companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets. It is a niche player in sterile injectables, oncology and ophthalmic solutions with focus on first-to-file, 505(b)(2) filings and NCE- 1s. Along with its partners Gland has 267 ANDA filings (101 owned) in the US as of Q1FY21, of which 215 were approved. The company has seven manufacturing facilities in India, comprising four formulations facilities with...
|
|
09 Nov 2020
|
Gland Pharma
|
Ashika Research
|
2022.80
|
|
|
|
IPO Note
|
|
|
The Company will not receive any proceeds of the Offer for Sale by the Selling Shareholder. (up to 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd, up to 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Ltd, up to 3,573,014 equity shares by Empower Discretionary Trust and up to 1,874,500...
|
|
08 Nov 2020
|
Gland Pharma
|
Ventura
|
2022.80
|
|
|
|
IPO Note
|
|
|
|
|
27 Jul 2020
|
Gland Pharma
|
Angel Broking
|
2022.80
|
|
|
|
IPO Note
|
|
|
Gland Pharma is one of the fastest growing generic injectable-focused companies by revenue in the United States from 2014 to 2019 as per IQVIA report. Company sells its products primarily under a B2B model which accounted for 97% of FY2020 revenues. Company exports to over 60 countries as of June 30, 2020, including the United
|